Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.


Rimon Law has added Dr. Peng Chen as a partner in the firm’s Litigation and Intellectual Property (IP) groups. While Dr. Chen’s practice is global, he will be based out of San Diego.

Dr. Chen joins Rimon from Morrison &Foerester LLP where he was a Partner.

Dr. Chen has been ranked in the fields of biotechnology law, patent law and patent litigation 2009-2018 by Best Lawyers. In 2018, Dr. Chen has been selected as a “Lawyer of the Year” in Patent Law in San Diego by Best Lawyers.  Dr. Chen has also been ranked as a regional expert on China intellectual property by Chambers Global.

Dr. Chen’s practice focuses on patent prosecution and strategic counseling, and he also is experienced in the areas of patent litigation, inter parties review, reexamination, interference, opposition, and licensing. He leads his biotechnology, pharmaceutical, and diagnostics clients through the technical and legal challenges involved in developing and protecting their critical IP assets.

At Rimon, Dr. Chen will be joining a strong IP team of Partners across the U.S. representing clients all over the globe. The IP team also works closely with the Corporate, Tax, Private Client and Litigation teams to ensure that our clients benefit from full-spectrum representation. Because of Rimon’s decentralized business model, Dr. Chen will be able to customize his service to each client to provide an optimal experience. ‘

“Life Science has been a booming part of the legal industry, as the pharmaceutical and biotech worlds continue to expand and needs top notch representation to handle the very challenging intellectual property issues.  Peng is at the very cutting edge of the biotech industry and his expertise will strengthen our biotech team. We are very glad to welcome Peng to Rimon,” said Michael Moradzadeh, CEO of Rimon.

Dr. Chen will be adding to Rimon’s Life Science practice group, which includes James ChapmanZheng LiuMark MirkinDennis Raglin, and Frank Vargas. Dr. Chen also adds to an esteemed list of Patent Prosecutors at Rimon, which includes Marc KaufmanLetao Qin and Robert Lee.

“I am very excited to join Rimon Law because in my view, Rimon offers an optimal structure for providing top quality client service in a cost-effective manner.  I am also very impressed by Rimon’s expertise in many crucial practice areas, such as corporate and licensing, and Rimon’s international reach including the rapidly growing China practice,” said Dr. Chen.

Dr. Chen is also going to add momentum to Rimon’s growing China practice along with Rimon Partners James ChapmanLetao QinAjay WhittemoreMarc Kaufman, Zheng LiuYaacov SilbermanJuan ZunigaRobert Q. LeeMatthew PoppeChris Terry and Fred Chang.

Dr. Chen earned his B.S. from Beijing Normal University in 1986, his Ph.D. from the John Hopkins University School of Medicine in 1993 and a J.D. in 1997 from Columbia Law School. He conducted his post-doctoral fellowship at Yale University School of Medicine and was a Harlan Fiske Stone Scholar while in law school.

Rimon has 17 offices across three continents. The firm is widely known as being at the vanguard of legal innovation. The firm has been repeatedly recognized by the Financial Times as one of North America’s most innovative law firms. The firm’s managing partners were both named ‘Legal Rebels’ by the American Bar Association’s ABA Journal and have spoken on innovations in the practice of law at Harvard and Stanford Law Schools. Rimon and its lawyers have also received numerous awards for excellence, including from Best Lawyers and Chambers.